Product Complaints and Quality Defects: Getting EU GMP Chapter 8 Right

Every complaint about a medicine, whether a cracked vial, an unusual smell or a missing leaflet, can be the first sign of a wider quality defect. Chapter 8 of the EU GMP Guide sets out how manufacturers and MAHs must handle complaints, investigate defects and, where necessary, recall product. Inspectors often treat a weak complaints system as a sign of a weak quality system overall.

The framework in Chapter 8

The current Chapter 8, Complaints, Quality Defects and Product Recalls, has applied since 1 March 2015. Compared with the earlier version, it put much more weight on quality risk management, root cause analysis and the effectiveness of corrective and preventive actions (CAPA). Its main expectations include:

  • trained personnel, with complaint handling independent of sales and marketing pressure
  • written procedures for receiving, assessing, investigating and closing complaints
  • a risk-based decision on each potential quality defect, including whether to notify competent authorities
  • attention to possible falsification and to adverse events linked to quality issues
  • regular trending of complaints to find recurring or systemic problems.

Investigation and root cause

Chapter 8 expects investigations proportionate to risk, with an appropriate level of root cause analysis. Good practice includes:

  • checking retained samples and batch records of the affected batch and related batches
  • considering whether other batches, strengths or products could be affected
  • using structured methods to avoid stopping at “human error” without understanding why the error occurred
  • setting CAPA in proportion to the risk and checking afterwards that it worked.

Where the root cause cannot be found, the most probable causes should be identified and addressed.

Recall decisions

A quality defect does not always mean a recall, but the decision must be risk-based, documented and timely. Chapter 8 recognises that a recall may be needed before the root cause investigation is complete, if patient risk justifies it. It also requires:

  • prompt notification of the competent authorities, including EOF in Greece, where a recall is being considered
  • a defined scope across the distribution chain, including wholesalers, pharmacies and hospitals
  • regular testing of recall arrangements, for example through mock recalls
  • reconciliation of recalled stock and an evaluation of how effective the recall was.

Links to pharmacovigilance and medical information

Complaints often arrive through medical information lines, sales representatives or adverse event reports. A complaint that involves harm to a patient is also a safety case, so clear interfaces between quality, pharmacovigilance and medical information are essential to make sure nothing falls between functions and that timelines are met on both sides.

How PQRA helps

PQRA reviews and builds complaint, quality defect and recall systems for manufacturers, MAHs and distributors. We draft procedures, train teams on investigation and root cause methods, facilitate mock recalls and align the quality and pharmacovigilance interfaces, so the system stands up to inspection and works when it matters.

Talk to PQRA about your complaints and recall system →

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *